Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above ...